Home » Topics » BioWorld Science

BioWorld Science
RSS

XC101-D13H as a promising new clinical-stage drug for the prevention of migraine

July 24, 2019

Translocator protein as a microglia activation marker in early-stage AD and DLB

July 24, 2019

Characterization of novel RORgamma inhibitors for the treatment of autoimmune disease

July 24, 2019

Samus Therapeutics announces the launch of PU-AD clinical program

July 24, 2019

Marinus Pharmaceuticals presents data from Magnolia and Amaryllis phase II studies

July 24, 2019

Favorable safety data announced for dose-escalation run-in of phase III INTACT study

July 24, 2019

BXCL-501 meets primary endpoint in phase Ib study for agitation associated with schizophrenia

July 24, 2019

COPD has autoimmune component

July 24, 2019

Deglycosylation predicts anti-PD-1/PD-L1 therapeutic efficacy

July 24, 2019

Inhaled alprazolam suppresses epileptiform activity in photosensitive participants with epilepsy

July 24, 2019

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...